Drug Status Key

  • Preferred
  • On Formulary
  • Specialist Initiation
  • Shared Care
  • Hospital Only
  • Under Review
  • New on System

2.12 Lipid-regulating drugs

Notes:

NICE has approved the use of the monoclonal antibodies, Alirocumab and Evolocumab to treat patients with primary hypercholesterolaemia or mixed dyslipidaemia where LDL-C concentrations remain above the threshold specified in the table below despite maximal tolerated lipid lowering therapy.

These treatments are self-administered by subcutaneous injection every 2 weeks.

Assessment, initiation, prescribing and monitoring of these treatments is through lipid clinics only.

Please note, sample information has been entered into Chapters 1 and 2 only and although fairly clinically accurate, it is not guaranteed. The information was entered during April and May 2017 and drugs will have subsequently been randomly added during telephone demonstrations.

Show All

Pack Price
28 tablet £26.31
30 tablet

Specialist input should be sought when prescribing a fibrate in combination with a statin.

Pack Price
28 tablet £4.50
30 tablet
Pack Price
100 tablet
14 tablet
28 tablet £0.87
30 tablet
84 tablet
90 tablet
Pack Price
10 tablet
14 tablet
28 tablet £0.97
30 tablet
84 tablet
90 tablet
Pack Price
28 tablet £1.18
30 tablet
90 tablet
Pack Price
28 tablet £1.85
30 tablet
90 tablet
Pack Price
28 tablet £0.80
Pack Price
28 tablet £0.93
Pack Price
28 tablet £18.03
30 tablet
98 tablet
Pack Price
28 tablet £26.02
30 tablet
98 tablet
Pack Price
28 tablet £29.69
Pack Price
28 tablet £18.03
30 tablet
90 tablet
Pack Price
1 pre-filled disposable injection
2 pre-filled disposable injection
Pack Price
1 pre-filled disposable injection
2 pre-filled disposable injection